Anti-Human CD182 (CXCR2) PE

Description: The eBio5E8-C7-F10 monoclonal antibody reacts with human CD182 (CXCR2, IL-8R beta). CD182 is a 67-70 kDa member of the seven-transmembrane spanning G-protein coupled receptor (GPCR) family. CD182 is expressed as a homodimer, or a heterodimer with CD181 (CXCR1, IL-8R alpha) and is expressed on granulocytes, NK cells, a subset of T cells, mast cells, monocytes, endothelial cells, megakaryocytes and oligodendrocytes. Binding of it's ligands, which include IL-8, NAP-2, GCP-2 and GRO alpha, -beta and -gamma, induces several biological outcomes such as cell activation, chemotaxis, proliferation and angiogenesis. There are several functional differences between CD181 and CD182. Both receptors are able to mediate chemotaxis and intracellular calcium changes, but only CD181 mediates phospolipase D activation and respiratory burst. Furthermore, studies have shown that IL-8 predominantly mediates its effects on neutrophil function through CD181.

References: Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol. 2000 Nov 1;165(9):5269-77.

Petering H, Gotze O, Kimmig D, Smolarski R, Kapp A, Elsner J. The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. Blood. 1999 Jan 15;93(2):694-702.

Jones SA, Dewald B, Clark-Lewis I, Baggiolini M. Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J Biol Chem. 1997 Jun 27;272(26):16166-9.

Chuntharapai A, Lee J, Hebert CA, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994 Dec 15;153(12):5682-8.

Sprenger H, Lloyd AR, Lautens LL, Bonner TI, Kelvin DJ. Structure, genomic organization, and expression of the human interleukin-8 receptor B gene. J Biol Chem. 1994 Apr 15;269(15):11065-72.